Matinas BioPharma’s upcoming Phase II initiation may open door to prescription omega fatty acid space

shutterstock_357287471
MAT9001 is being developed for therapeutic applications in the dyslipidemia field and is targeting severe hypertriglyceridemia as its primary indication.